AR048333A1 - Metodos de tratamiento de infeccion de vih - Google Patents

Metodos de tratamiento de infeccion de vih

Info

Publication number
AR048333A1
AR048333A1 ARP050101159A ARP050101159A AR048333A1 AR 048333 A1 AR048333 A1 AR 048333A1 AR P050101159 A ARP050101159 A AR P050101159A AR P050101159 A ARP050101159 A AR P050101159A AR 048333 A1 AR048333 A1 AR 048333A1
Authority
AR
Argentina
Prior art keywords
hiv
inhibitors
treatment
hiv infection
aids
Prior art date
Application number
ARP050101159A
Other languages
English (en)
Spanish (es)
Inventor
Pin-Fang Lin
Nowicka-Sans Beata
Gregory Yamanaka
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR048333A1 publication Critical patent/AR048333A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP050101159A 2004-03-24 2005-03-23 Metodos de tratamiento de infeccion de vih AR048333A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24

Publications (1)

Publication Number Publication Date
AR048333A1 true AR048333A1 (es) 2006-04-19

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101159A AR048333A1 (es) 2004-03-24 2005-03-23 Metodos de tratamiento de infeccion de vih

Country Status (30)

Country Link
US (1) US7776863B2 (cg-RX-API-DMAC7.html)
EP (1) EP1732604B1 (cg-RX-API-DMAC7.html)
JP (1) JP4847441B2 (cg-RX-API-DMAC7.html)
KR (1) KR101158140B1 (cg-RX-API-DMAC7.html)
CN (1) CN1956720B (cg-RX-API-DMAC7.html)
AR (1) AR048333A1 (cg-RX-API-DMAC7.html)
AT (1) ATE474602T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005235116B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0509140A (cg-RX-API-DMAC7.html)
CA (1) CA2561146C (cg-RX-API-DMAC7.html)
CY (1) CY1111613T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005022420D1 (cg-RX-API-DMAC7.html)
DK (1) DK1732604T3 (cg-RX-API-DMAC7.html)
ES (1) ES2347801T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20104925B (cg-RX-API-DMAC7.html)
HR (1) HRP20100434T1 (cg-RX-API-DMAC7.html)
IL (1) IL178141A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN06436A (cg-RX-API-DMAC7.html)
MY (1) MY144318A (cg-RX-API-DMAC7.html)
NO (1) NO337116B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ549778A (cg-RX-API-DMAC7.html)
PE (1) PE20060148A1 (cg-RX-API-DMAC7.html)
PL (1) PL1732604T3 (cg-RX-API-DMAC7.html)
PT (1) PT1732604E (cg-RX-API-DMAC7.html)
RU (1) RU2367439C2 (cg-RX-API-DMAC7.html)
SI (1) SI1732604T1 (cg-RX-API-DMAC7.html)
TW (1) TWI347184B (cg-RX-API-DMAC7.html)
UA (1) UA88463C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005102392A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200607959B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US8318931B2 (en) 2005-10-28 2012-11-27 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
ES2462403T3 (es) 2008-06-25 2014-05-22 Bristol-Myers Squibb Company Diceto azolopiperidinas y azolopiperazinas como agentes anti-VIH
US8242124B2 (en) * 2008-06-25 2012-08-14 Bristol-Myers Squibb Company Diketopiperidine derivatives as HIV attachment inhibitors
US20110290821A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
EP2601174B1 (en) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
RS54055B1 (sr) 2011-01-31 2015-10-30 Bristol-Myers Squibb Company POSTUPCI ZA PRIPREMU JEDINJENJA PROLEKA INHIBITORA VEZIVANJA HIV-a I INTERMEDIJERA
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2616268T3 (es) 2011-08-29 2017-06-12 VIIV Healthcare UK (No.5) Limited Derivados condensados de diamina bicíclica como inhibidores de la unión de VIH
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
PT2978763T (pt) * 2013-03-27 2018-04-16 Viiv Healthcare Uk No 5 Ltd Derivados de 2-cetoamida como inibidores da ligação do vih
EP3313412A4 (en) 2015-06-23 2019-01-16 CytoDyn Inc. INHIBITION OF CCL5 LIGAND BINDING AT CCR5 RECEPTOR AND CHANGING CCR5 / CCL5 AXIS SIGNALING IN INFUSION, CANCER, AUTOIMMUNE AND OTHER DISORDERS
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348839T1 (de) * 1998-03-02 2007-01-15 Univ North Carolina Acylierte betulin- und dihydrobetulinderivate, ihre herstellung und verwendung
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
WO2003049690A2 (en) * 2001-12-12 2003-06-19 Bristol-Myers Squibb Company Hiv integrase inhibitors
CN102153540A (zh) * 2001-12-21 2011-08-17 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物

Also Published As

Publication number Publication date
JP2007530540A (ja) 2007-11-01
EP1732604A2 (en) 2006-12-20
GEP20104925B (en) 2010-03-25
US20050215545A1 (en) 2005-09-29
NZ549778A (en) 2010-09-30
DE602005022420D1 (de) 2010-09-02
DK1732604T3 (da) 2010-11-15
JP4847441B2 (ja) 2011-12-28
UA88463C2 (ru) 2009-10-26
WO2005102392A3 (en) 2006-07-20
CN1956720B (zh) 2010-12-15
HK1096540A1 (en) 2007-06-01
AU2005235116A1 (en) 2005-11-03
US7776863B2 (en) 2010-08-17
RU2006137555A (ru) 2008-04-27
IL178141A0 (en) 2006-12-31
ES2347801T3 (es) 2010-11-04
NO20064547L (no) 2006-10-06
IL178141A (en) 2010-11-30
PL1732604T3 (pl) 2010-12-31
CY1111613T1 (el) 2015-10-07
MY144318A (en) 2011-08-29
HRP20100434T1 (hr) 2010-09-30
AU2005235116B2 (en) 2011-03-31
CN1956720A (zh) 2007-05-02
RU2367439C2 (ru) 2009-09-20
PT1732604E (pt) 2010-09-24
EP1732604B1 (en) 2010-07-21
BRPI0509140A (pt) 2007-09-04
SI1732604T1 (sl) 2010-10-29
PE20060148A1 (es) 2006-03-04
CA2561146C (en) 2013-12-24
NO337116B1 (no) 2016-01-25
TW200538117A (en) 2005-12-01
KR20070011322A (ko) 2007-01-24
CA2561146A1 (en) 2005-11-03
ZA200607959B (en) 2008-06-25
WO2005102392A2 (en) 2005-11-03
KR101158140B1 (ko) 2012-06-19
ATE474602T1 (de) 2010-08-15
IN2012DN06436A (cg-RX-API-DMAC7.html) 2015-10-09
TWI347184B (en) 2011-08-21

Similar Documents

Publication Publication Date Title
AR048333A1 (es) Metodos de tratamiento de infeccion de vih
AR048324A1 (es) Metodos para tratar infecciones por vih
AR048439A1 (es) Composiciones farmaceuticas y metodos para tratar la infeccion por vih
BRPI0415649A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
UY25869A1 (es) Moduladores de ccr5, formulaciones farmacéuticas, procedimientos y sus usos.
PA8603201A1 (es) Procedimiento y composiciones farmaceuticas para el tratamiento de arterosclerosis, dislipidemias y afecciones relacionadas
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
Goto et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
RU2010151660A (ru) Способы лечения множественной миеломы
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
PA8517701A1 (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
RU2005131578A (ru) Аплидин для лечения множественной миеломы
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
BRPI0416266A (pt) método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
AR045074A1 (es) Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
BRPI0415970A (pt) método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica
RU2548739C1 (ru) Способ лечения реперфузионного синдрома у больных сахарным диабетом после реваскуляризирующих операций на артериях нижних конечностей

Legal Events

Date Code Title Description
FC Refusal